Skip to main content
. 2017 Mar 26;14(3):225–233. doi: 10.1177/1740774517700640

Table 1.

Safety reporting definitions.a

Term Definition
Adverse event (AE) Any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related.
Adverse reaction Any adverse event caused by a drug.
Suspected adverse reaction Any AE for which there is a reasonable possibility that the drug caused the adverse event. For the purposes of investigational new drug (IND) safety reporting, “reasonable possibility” means there is evidence to suggest a causal relationship between the drug and the adverse event. A suspected adverse reaction implies a lesser degree of certainty than an adverse reaction.
Unexpected An AE or suspected adverse reaction is considered “unexpected” if it is not listed in the investigator brochure, is not listed at the specificity or severity that has been observed, or, if an investigator brochure is not required or available, is not consistent with the risk information described in the general investigational plan or elsewhere in the current application, as amended.
Anticipated For the purposes of IND safety reporting, anticipated serious AEs are serious AEs that the sponsor can foresee occurring with some frequency, independent of investigational drug exposure, in the general patient population under study, in patients with the disease under study, or both.
Serious An AE or suspected adverse reaction that results in any of the following outcomes: death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or a congenital anomaly/birth defect.
Analysis of similar events The sponsor must identify in each IND safety report all IND safety reports previously submitted to Food and Drug Administration (FDA) concerning a similar suspected adverse reaction and must analyze the significance of the suspected adverse reaction in light of previous, similar reports or any other relevant information.
a

Definitions were derived from Food and Drug Administration.2,7